Real-World study shows cariprazine eases depression in bipolar i patients
NCT ID NCT06256367
First seen Nov 01, 2025 · Last updated May 10, 2026 · Updated 25 times
Summary
This study followed 120 adults with bipolar I disorder who were starting cariprazine (Vraylar) for a depressive episode. Researchers measured changes in depression symptoms, daily functioning, and quality of life over 24 weeks in routine clinic visits. The goal was to see how well the medication works outside of strict trial conditions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIPOLAR I DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Betts Psychiatric, PC /ID# 259737
Eugene, Oregon, 97401-6008, United States
-
Bowman Medical Group /ID# 259989
Beverly Hills, California, 90212-1910, United States
-
Chatham-Kent Clinical Trials /ID# 262414
Chatham, Ontario, N7L 1C1, Canada
-
Clinique Woodward /ID# 264050
Sherbrooke, Quebec, J1G 2N5, Canada
-
Douglas Mental Health University Institute /ID# 262048
Verdun, Quebec, H4H 1R2, Canada
-
Georgia Psychiatric Consultants & Advanced Discovery Research /ID# 259975
Atlanta, Georgia, 30318-3102, United States
-
Grand River Hospital /ID# 263962
Kitchener, Ontario, N2G 1G3, Canada
-
Institut universitaire en santé mentale de Montréal /ID# 264665
Montreal, Quebec, H1N 3M5, Canada
-
Montano Wellness LLC /ID# 259837
Cromwell, Connecticut, 06416, United States
-
North Star Medical Research LL /ID# 259730
Middleburg Heights, Ohio, 44130, United States
-
Omaha Insomnia and Psychiatric Services /ID# 259961
Omaha, Nebraska, 68144-2359, United States
-
Quest Therapeutics of Avon /ID# 259838
Avon Lake, Ohio, 44012-1004, United States
-
Rivus Wellness And Research Institute /ID# 259966
Oklahoma City, Oklahoma, 73112, United States
-
START Clinic for Mood and Anxiety Disorders /ID# 262416
Toronto, Ontario, M4W 2N4, Canada
-
Southlake Regional Health Centre /ID# 264212
Newmarket, Ontario, L3Y 2P9, Canada
-
Sunny Johnson Medical Research Associates /ID# 267713
Mississauga, Ontario, L5M 4N4, Canada
-
UC Davis /ID# 259723
Sacramento, California, 95817-2310, United States
-
University of Alabama at Birmingham - Main /ID# 260000
Birmingham, Alabama, 35233, United States
-
Ut Southwestern Medical Center /Parkland Health and Hospital System /Id# 260001
Dallas, Texas, 75235-7709, United States
Conditions
Explore the condition pages connected to this study.